SE9700885D0 - New pharmaceutical formulation - Google Patents
New pharmaceutical formulationInfo
- Publication number
- SE9700885D0 SE9700885D0 SE9700885A SE9700885A SE9700885D0 SE 9700885 D0 SE9700885 D0 SE 9700885D0 SE 9700885 A SE9700885 A SE 9700885A SE 9700885 A SE9700885 A SE 9700885A SE 9700885 D0 SE9700885 D0 SE 9700885D0
- Authority
- SE
- Sweden
- Prior art keywords
- dosage form
- pharmaceutical formulation
- new pharmaceutical
- unit tableted
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An enteric coated oral dosage form comprising sodium amoxycillin, wherein the dosage form is a single unit tableted dosage form or a multiple unit tableted dosage form is claimed. Processes for the manufacture of the dosage forms as well as the formulations, use in the treatment of Helicobacter pylori infections are claimed.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9700885A SE9700885D0 (en) | 1997-03-12 | 1997-03-12 | New pharmaceutical formulation |
JP53949898A JP2001515489A (en) | 1997-03-12 | 1998-02-27 | Enteric coated oral dosage form consisting of amoxicillin sodium |
EP98909899A EP0981335A1 (en) | 1997-03-12 | 1998-02-27 | An enteric coated oral dosage form comprising sodium amoxycillin |
AU64268/98A AU6426898A (en) | 1997-03-12 | 1998-02-27 | An enteric coated oral dosage form comprising sodium amoxycillin |
PCT/SE1998/000356 WO1998040054A1 (en) | 1997-03-12 | 1998-02-27 | An enteric coated oral dosage form comprising sodium amoxycillin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9700885A SE9700885D0 (en) | 1997-03-12 | 1997-03-12 | New pharmaceutical formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
SE9700885D0 true SE9700885D0 (en) | 1997-03-12 |
Family
ID=20406120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE9700885A SE9700885D0 (en) | 1997-03-12 | 1997-03-12 | New pharmaceutical formulation |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0981335A1 (en) |
JP (1) | JP2001515489A (en) |
AU (1) | AU6426898A (en) |
SE (1) | SE9700885D0 (en) |
WO (1) | WO1998040054A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69617036T2 (en) | 1995-09-07 | 2002-07-11 | Smithkline Beecham Corp., King Of Prussia | USE OF A PEDIATRIC PHARMACEUTICAL FORMULATION CONTAINING AMOXICILLIN AND CLAVULANATE |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6294199B1 (en) * | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
EA004310B1 (en) * | 1999-04-13 | 2004-02-26 | Бичам Фармасьютикалз (Пте) Лимитед | Novel method of treatment |
US6878386B1 (en) | 1999-04-13 | 2005-04-12 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate |
US7250176B1 (en) | 1999-04-13 | 2007-07-31 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection |
US6756057B2 (en) | 2000-10-12 | 2004-06-29 | Beecham Pharmaceuticals (Pte) Limited | Amoxicillin and potassium clavulanate dosage form |
AU2001292185A1 (en) | 2000-10-12 | 2002-04-22 | Beecham Pharmaceuticals (Pte) Limited | Formulation containing amoxicillin |
GB0031267D0 (en) * | 2000-12-21 | 2001-01-31 | Smithkline Beecham Plc | Novel compositions |
SE0101379D0 (en) * | 2001-04-18 | 2001-04-18 | Diabact Ab | Composition that inhibits gastric acid secretion |
ES2198195B1 (en) * | 2001-12-18 | 2004-10-01 | Laboratorios Del Dr. Esteve, S.A. | COMPRESSED ORAL PHARMACEUTICAL DOSAGE FORM, WITH ENTERIC COATING, CONTAINING A LABIL BENCIMIDAZOL COMPOUND IN THE MIDDLE ACID. |
SE0203065D0 (en) | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8168228B2 (en) * | 2003-10-17 | 2012-05-01 | Sandoz Ag | Antibiotic clarithromycin micropellet compositions |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
RU2006132127A (en) * | 2006-09-06 | 2008-03-20 | Государственное Учреждение Научный Центр Здоровьядетей Российской Академии Медицинских Наук (Гу Нцзд Рамн) (Ru) | APPLICATION OF NIFUROXASIDE AS A COMPONENT OF COMBINED MEDICINE THERAPY OF DISEASES ASSOCIATED WITH HELICOBACTER PYLORI, AND A METHOD OF TREATMENT AIMED AT ERADICATION OF AN ACTIVATOR |
CN109893516A (en) | 2013-02-13 | 2019-06-18 | 红山生物医药有限公司 | For treating the pharmaceutical composition of helicobacter pylori |
CN107405338A (en) * | 2015-01-09 | 2017-11-28 | 加州大学评议会 | For treating the composition and method of alimentary infection |
US11878011B2 (en) | 2020-05-07 | 2024-01-23 | Redhill Biopharma Ltd. | Method for eradicating Helicobacter pylori infection in patients regardless of body mass index |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9201930D0 (en) * | 1992-06-24 | 1992-06-24 | Astra Ab | GASTRIC ANTIBACTERIAL TREATMENT |
GB9405856D0 (en) * | 1994-03-24 | 1994-05-11 | Smithkline Beecham Plc | Pharmaceutical formulation |
US5945124A (en) * | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
-
1997
- 1997-03-12 SE SE9700885A patent/SE9700885D0/en unknown
-
1998
- 1998-02-27 EP EP98909899A patent/EP0981335A1/en not_active Withdrawn
- 1998-02-27 JP JP53949898A patent/JP2001515489A/en active Pending
- 1998-02-27 AU AU64268/98A patent/AU6426898A/en not_active Abandoned
- 1998-02-27 WO PCT/SE1998/000356 patent/WO1998040054A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2001515489A (en) | 2001-09-18 |
AU6426898A (en) | 1998-09-29 |
WO1998040054A1 (en) | 1998-09-17 |
EP0981335A1 (en) | 2000-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE9700885D0 (en) | New pharmaceutical formulation | |
MX9604354A (en) | New oral pharmaceutical dosage form. | |
ID27504A (en) | NEW ORAL FORMULATION | |
EE200000329A (en) | Oral Form For Acid-Unstable Active Ingredients, Method Of Preparation And Use Of A Unit Of Acid-Unstable Active Ingredient | |
BR0107565A (en) | Replaced benzimidazole dosage forms and methods of use | |
CL2009001279A1 (en) | Nociceptin derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of pain (sol. divisional 2103-03). | |
CY1107675T1 (en) | TRAMADOLIS MEDICINES | |
IS4146A (en) | A pharmaceutical preparation for oral administration of proton pump blockers | |
NO20012222L (en) | Pharmaceutical formulation including omeprazole | |
HUP0201877A2 (en) | Fast-dispersing dosage forms containing fish gelatin | |
HUP0004383A2 (en) | Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient | |
ATE211907T1 (en) | OSMOTIC DRUG RELEASE SYSTEM | |
SE9504661D0 (en) | New compounds | |
HUP0104318A2 (en) | Controlled-release pharmaceutical formulations containing acgmp pde-5 inhibitor | |
DE60019334D1 (en) | ANTIVIRAL ARZNEI | |
HUP0301349A2 (en) | Formulations for il-11 | |
NO20034863L (en) | Deuterated 3-piperidinopropiophenone as well as drugs containing these compounds | |
DE50005529D1 (en) | ORAL PHARMACEUTICAL FORMS FOR ADMINISTRATING A FIXED COMBINATION OF TRAMADOL AND DICLOFENAC | |
HUP0104647A2 (en) | Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient | |
ID28510A (en) | NEW ORAL FORMULATION FOR AGONISTS OR 5-HT4 ANTAGONISTS | |
DE60102590T2 (en) | PHARMACEUTICAL FORMS FOR THE TREATMENT OF ORAL MYCOSES | |
RS50298B (en) | Directly compressibile matrix for controlled release of single daily doses of clarithromycin | |
HUP9801924A2 (en) | Pharmaceutical composition containing sodium-hydrogen-exchange-inhibitors and cardiovascular active agents | |
ATE360428T1 (en) | ANALGESIC MEDICINAL PRODUCT | |
IS6532A (en) | Dosage formulation for oral administration of ziprofloxacin once daily |